



Sen. Linda Holmes

**Filed: 3/9/2015**

09900SB1359sam001

LRB099 03770 MLM 32024 a

1 AMENDMENT TO SENATE BILL 1359

2 AMENDMENT NO. \_\_\_\_\_. Amend Senate Bill 1359 by replacing  
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Insurance Code is amended by  
5 adding Section 356z.23 as follows:

6 (215 ILCS 5/356z.23 new)

7 Sec. 356z.23. Specialty tier prescription coverage.

8 (a) As used in this Section:

9 "Coinsurance" means a cost-sharing amount set as a  
10 percentage of the total cost of a drug.

11 "Copayment" means a cost-sharing amount set as a dollar  
12 value.

13 "Non-preferred drug" means a drug in a tier designed for  
14 certain drugs deemed non-preferred and therefore subject to  
15 higher cost-sharing amounts than preferred drugs.

16 "Preferred drug" means a drug in a tier designed for

1 certain drugs deemed preferred and therefore subject to lower  
2 cost-sharing amounts than non-preferred drugs.

3 "Tiered formulary" means a formulary that provides  
4 coverage for prescription drugs as part of a policy of health  
5 and accident insurance for which cost sharing, deductibles, or  
6 coinsurance obligations are determined by category or tier of  
7 prescription drugs and includes at least 2 different tiers.

8 (b) On or after the effective date of this amendatory Act  
9 of the 99th General Assembly, every insurer that amends,  
10 delivers, issues, or renews individual and group accident and  
11 health policies providing coverage for prescription drugs  
12 shall ensure that:

13 (1) for insurance plans rated platinum, gold, and  
14 silver level, as defined in 45 CFR 156.140, and regardless  
15 of whether or not the plan was acquired through an exchange  
16 authorized under the federal Patient Protection and  
17 Affordable Care Act, any required copayment or coinsurance  
18 applicable to drugs does not exceed \$100 per month for up  
19 to a 30-day supply of any single drug; and

20 (2) for bronze plans, as defined in 45 CFR 156.140, and  
21 regardless of whether or not the plan was acquired through  
22 an exchange authorized under the federal Patient  
23 Protection and Affordable Care Act, any required copayment  
24 or coinsurance applicable to drugs does not exceed \$200 per  
25 month for up to a 30-day supply of any single drug.

26 (c) The limits described in subsection (b) of this Section

1 shall be inclusive of any patient out-of-pocket spending,  
2 including payments towards any deductibles, copayments, or  
3 coinsurance and shall be applicable before any applicable  
4 deductible is reached.

5 (d) An insurance plan that meets the requirements for a  
6 catastrophic plan, as defined in 45 CFR 156.155(a), shall be  
7 exempt from the requirements of subsection (b) of this Section.

8 (e) Subject to subsection (f) of this Section, the limits  
9 in subsection (b) of this Section shall apply at any point in  
10 the benefit design, including before any after any applicable  
11 deductible is reached.

12 (f) For any enrollee that is enrolled in a policy that, but  
13 for the requirements of subsection (b) of this Section, would  
14 be a high deductible health plan as defined in Section  
15 223(c)(2)(A) of the Internal Revenue Code of 1986, the limits  
16 described in subsection (b) of this Section shall be applicable  
17 only after the minimum annual deductible specified in Section  
18 223(c)(2)(A) of the Internal Revenue Code of 1986 is reached.

19 (g) An insurer that issues policies of accident and health  
20 insurance that provides coverage for prescription drugs shall  
21 implement an exceptions process that allows enrollees to  
22 request an exception to the formulary. An insurer may use its  
23 existing medical exceptions process to satisfy this  
24 requirement. Under such an exception, a non-formulary drug  
25 shall be deemed covered under the formulary if the prescribing  
26 physician determines that the formulary drug for treatment of

1 the same condition either would not be as effective for the  
2 individual, or would have adverse effects for the individual,  
3 or both. If an enrollee is denied an exception, the denial  
4 shall be considered an adverse coverage determination and will  
5 be subject to the health plan internal and external review  
6 processes.

7 (h) On or after the effective date of this amendatory Act  
8 of the 99th General Assembly, every insurer that amends,  
9 delivers, issues, or renews individual and group accident and  
10 health policies providing coverage for prescription drugs  
11 shall ensure that beneficiary's annual out-of-pocket  
12 expenditures for prescription drugs are limited to no more than  
13 50% of the dollar amounts in effect under Section 1302(c) (1) of  
14 the federal Patient Protection and Affordable Care Act for  
15 self-only and family coverage, respectively.

16 (i) An insurer that issues policies of accident and health  
17 policies that provides coverage for prescription drugs and uses  
18 a tiered formulary shall implement an exceptions process that  
19 allows enrollees to request an exception to the tiered  
20 cost-sharing structure. Under an exception, a non-preferred  
21 drug may be covered under the cost sharing applicable for  
22 preferred drugs if the prescribing health care provider  
23 determines that the preferred drug for treatment of the same  
24 condition either would not be as effective for the individual,  
25 would have adverse effects for the individual, or both. If an  
26 enrollee is denied a cost-sharing exception, the denial shall

1 be considered an adverse event and shall be subject to the  
2 health plan's internal review process.

3 (j) Nothing in this Section shall be construed to require  
4 an insurer that issues accident and health policies:

5 (1) provide coverage for any additional drugs not  
6 otherwise required by law;

7 (2) implement specific utilization management  
8 techniques, such as prior authorization or step therapy; or

9 (3) cease utilization of tiered cost-sharing  
10 structures, including those strategies used to incentivize  
11 use of preventive services, disease management, and  
12 low-cost treatment options.

13 (k) Nothing in this Section shall be construed to require a  
14 pharmacist to substitute a drug without the consent of the  
15 prescribing physician.

16 (l) The Director shall adopt rules outlining the  
17 enforcement processes for this Section.

18 Section 99. Effective date. This Act takes effect January  
19 1, 2016."